Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 27, 2021 at 11:12 pm EDT
Share
Henan Lingrui Pharmaceutical Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 589.387 million compared to CNY 491.104 million a year ago. Operating income was CNY 112.911 million compared to CNY 90.097 million a year ago. Net income was CNY 96.577 million compared to CNY 76.533 million a year ago. Basic earnings per share from continuing operations was CNY 0.17 compared to CNY 0.135 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
HENAN LINGRUI PHARMACEUTICAL CO., LTD. 
